Earnings ·
Abeona Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing net ZEVASKYN revenue…
ABEOAbeona Therapeutics Inc.
Abeona Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing net ZEVASKYN revenue of $11.4 million, a 31% increase from the prior quarter. The company treated five patients with its gene therapy product during the period and holds $146.8 million in cash and short-term investments. Abeona also announced that CMS will grant New Technology Add-On Payment status for ZEVASKYN starting October 1, 2026, facilitating access for Medicare beneficiaries. The company operates as a commercial-stage biopharmaceutical firm developing cell and gene therapies.